Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01886859 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

NIH

Sponsor class

Conditions

Recurrent B-Cell Prolymphocytic Leukemia
Recurrent Chronic Lymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory B-Cell Prolymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Refractory Small Lymphocytic Lymphoma

Interventions

DRUG: Ibrutinib
DRUG: Lenalidomide

Sponsor

National Cancer Institute (NCI)